Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma

被引:0
|
作者
Fernanda Maria Santos
Jose Flavio Gomes Marin
Marcos Santos Lima
Wellington Fernandes Silva-Junior
Lucas Bassolli O. Alves
Frederico R. Moreira
Rodrigo Dolphini Velasques
Marcelo Junqueira Atanazio
Ana Carolina Arrais Maia
Carlos A. Buchpiguel
Valeria Buccheri
Vanderson Rocha
机构
[1] Faculdade de Medicina,Instituto Do Cancer Do Estado de Sao Paulo (ICESP)
[2] Universidade de Sao Paulo (FMUSP),Nuclear Medicine Medical Investigation Laboratory LIM43
[3] Hospital das Clinicas,Division of Hematology and Cell Therapy
[4] FMUSP (HCFMUSP),Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco
[5] HCFMUSP,Immuno
[6] HCFMUSP,Hematology (LIM
[7] Churchill Hospital,31), Department of Internal Medicine, Division of Hematology
[8] NHS BT,Department of Hematology
[9] Oxford University,undefined
来源
Annals of Hematology | 2024年 / 103卷
关键词
Hodgkin lymphoma; Positron emission tomography; Metabolic tumor volume; Total lesion glycolysis;
D O I
暂无
中图分类号
学科分类号
摘要
Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUVmax, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4–5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUVmax, ΔTMTV and ΔTLG, only a ΔSUVmax ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11–0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUVmax ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUVmax to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.
引用
收藏
页码:175 / 183
页数:8
相关论文
共 50 条
  • [41] Prognostic value of massiveness parameters measured on baseline FDG PET in advanced-stage Hodgkin lymphoma
    Draye-Carbonnier, S.
    Mihailescu, S.
    Pinochet, P.
    Texte, E.
    Stamatoullas-Bastard, A.
    Vera, P.
    Becker, S.
    Decazes, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S575 - S575
  • [42] The prognostic role of qPET in interim-PET in paediatric Hodgkin lymphoma
    Pacella, Sara
    Landoni, Claudio
    Bonacina, Manuela
    Morzenti, Sabrina
    Elena, De Ponti
    Sala, Alessandra
    Guerra, Luca
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [43] Interim-PET As a Predictive Factor in Patients with Hodgkin's Lymphoma
    Kryachok, Irina
    Novosad, Olga
    Pastushenko, Ian
    Skrypets, Tetiana
    Kadnikova, Tetiana
    Tytorenko, Iryna
    Kushchevyy, Evgen
    Ulianchenko, Kateryna
    Filonenko, Kateryna
    Stepanishyna, Yana
    Aleksik, Olena
    Kmetyuk, Yaroslav
    Karpova, Olga
    Mykhalska, Larisa
    Kindrakevych, Olga
    Pylypenko, Halyna
    Lukjanec, Olena
    Duma, Viktor
    Kozlov, Viktor
    Batyuk, Liliya
    Ryzhak, Olena
    Strembitska, Nataliia
    Chikalova, Hanna
    Chupryna, Myroslava
    Kozlov, Iurii
    Novikov, Mykola
    Kosinova, Viktoriia
    Oliinichenko, Olena
    Lola, Olena
    Kholodna, Alina
    Loza, Olga
    Kostiukova, Nina
    Tkachenko, Oksana
    Karnabeda, Oksana
    Stratienko, Viktoriya
    Gorbach, Oleksandr
    Danilov, Alexey
    BLOOD, 2017, 130
  • [44] The predictive value of Interim PET and Immunohistochemical markers in Hodgkin Lymphoma (HL)
    Zanoni, L.
    Agostinelli, C.
    Gallamini, A.
    Rigacci, L.
    Sista, M.
    Piccaluga, P.
    Broccoli, A.
    Argnani, L.
    Zinzani, P.
    Pileri, S.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S165 - S165
  • [45] The role of PET for interim response assessment in patients with Hodgkin's lymphoma
    Zaucha, Jan
    Danielewicz, Iwona
    Malkowski, Bogdan
    Zaucha, Renata
    Lesniewski-Kmak, Krzysztof
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (04): : 161 - 166
  • [46] Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
    Epperla, Narendranath
    Costa, Luciano J.
    Vaughn, John L.
    Hanel, Walter
    Raya, Saba
    Cashen, Amanda F.
    Sarmad, Rehan
    Badar, Talha
    Hamadani, Mehdi
    Liu, Yang
    Barta, Stefan K.
    Caimi, Paolo
    Sethi, Tarsheen K.
    Reddy, Nishitha
    Burkart, Madelyn
    Karmali, Reem
    Bello, Celeste
    Chavez, Julio C.
    Kothari, Shalin K.
    Hernandez-Ilizaliturri, Francisco J.
    Ballard, Hatcher J.
    Svoboda, Jakub
    Emery, Lukas
    Lansigan, Frederick
    Glenn, Martha
    Churnetski, Michael C.
    Cohen, Jonathon B.
    Sorge, Caryn
    Xavier, Ana C.
    BLOOD, 2019, 134
  • [47] Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
    Diane Tseng
    Leelanand P Rachakonda
    Zheng Su
    Ranjana Advani
    Sandra Horning
    Richard T Hoppe
    Andrew Quon
    Edward E Graves
    Billy W Loo
    Phuoc T Tran
    Radiation Oncology, 7
  • [48] Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
    Tseng, Diane
    Rachakonda, Leelanand P.
    Su, Zheng
    Advani, Ranjana
    Horning, Sandra
    Hoppe, Richard T.
    Quon, Andrew
    Graves, Edward E.
    Loo, Billy W., Jr.
    Tran, Phuoc T.
    RADIATION ONCOLOGY, 2012, 7
  • [49] Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma
    Schwiebert, Ralph
    Barrans, Sharon
    Taylor, Jan
    Jack, Andrew S.
    Burton, Cathy H.
    BLOOD, 2015, 126 (23)
  • [50] The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma (vol 87, pg 937, 2012)
    Nussenzveig, Roberto H.
    Vanhille, Derek L.
    Hussey, Dottie
    Reading, N. Scott
    Agarwal, Archana M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : E136 - E136